Di Carlo Costantino, Gargano Virginia, Sparice Stefania, Tommaselli Giovanni A, Bifulco Giuseppe, Schettino Daniela, Nappi Carmine
Department of Obstetrics and Gynaecology, University of Naples Federico II , Naples , Italy.
Eur J Contracept Reprod Health Care. 2013 Oct;18(5):388-93. doi: 10.3109/13625187.2013.811483. Epub 2013 Jul 16.
To evaluate the effects of a combined oral contraceptive (COC) containing dienogest/oestradiol valerate (DNG/E2V) on bone mineral density (BMD) and on serum and urinary bone turnover markers in young, healthy, fertile women.
At baseline and after three and six months of intake of the aforementioned COC, serum and urinary calcium, osteocalcin, urinary pyridinoline (PYD), and deoxypyridinoline (D-PYD) of 30 women aged 21 to 34 years were measured. At baseline and after six months, lumbar bone mineral density was determined by dual-energy X-ray absorptiometry (DEXA).
Urinary levels of PYD and D-PYD were significantly lower at three and six months in comparison with basal values (p < 0.05). Serum calcium levels showed an increasing trend, which reached statistical significance after six months in comparison with basal values while urinary levels of calcium did not vary significantly. Serum osteocalcin levels were somewhat, but not significantly, lower during pill use in comparison with basal values. After six months, spinal BMD values did not differ significantly from basal values.
The DNG/E2V COC has no short-term adverse effect on bone turnover markers. No significant change in BMD was observed after six months of use of that pill.
评估含有地诺孕素/戊酸雌二醇（DNG/E2V）的复方口服避孕药（COC）对年轻、健康、有生育能力女性的骨矿物质密度（BMD）以及血清和尿骨转换标志物的影响。
在30名年龄在21至34岁的女性摄入上述COC的基线期、3个月和6个月后，测量其血清和尿钙、骨钙素、尿吡啶啉（PYD）和脱氧吡啶啉（D-PYD）。在基线期和6个月后，通过双能X线吸收法（DEXA）测定腰椎骨矿物质密度。
与基线值相比，3个月和6个月时尿PYD和D-PYD水平显著降低（p<0.05）。血清钙水平呈上升趋势，与基线值相比，6个月后达到统计学显著性，而尿钙水平无显著变化。与基线值相比，服药期间血清骨钙素水平略有降低，但无统计学显著性。6个月后，脊柱BMD值与基线值无显著差异。
DNG/E2V COC对骨转换标志物无短期不良影响。服用该避孕药6个月后，未观察到BMD有显著变化。
